menu
    • menu
    [{"orgOrder":0,"company":"HTL Biotechnology","sponsor":"Eirion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Botulinum toxin type A","moa":"Ach release","graph1":"Dermatology","graph2":"Phase II","graph3":"HTL Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Liniment","sponsorNew":"HTL Biotechnology \/ Eirion Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"HTL Biotechnology \/ Eirion Therapeutics"},{"orgOrder":0,"company":"HTL Biotechnology","sponsor":"GelMEDIX","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"HTL Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Hydrogel Implant","sponsorNew":"HTL Biotechnology \/ HTL","highestDevelopmentStatusID":"1","companyTruncated":"HTL Biotechnology \/ HTL"},{"orgOrder":0,"company":"HTL Biotechnology","sponsor":"Biophta","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"BO-001","moa":"","graph1":"Technology","graph2":"Approved","graph3":"HTL Biotechnology","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"HTL Biotechnology \/ HTL Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"HTL Biotechnology \/ HTL Biotechnology"}]

    Find Clinical Drug Pipeline Developments & Deals by HTL Biotechnology

    Menu

    HTL Biotechnology

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    SERVICES

    Key Services KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HTL Biotechnology

                            France
                            PCHi
                            Booth #5J24
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothHTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

                            Lead Product(s) : BO-001

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Recipient : Biophta

                            Deal Size : $6.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            BIOPHTA Raises 6.5M Euros Funding to Transition its New Standard of Care for Eye Diseases

                            Details : The financing aims to fund the first-in-human trial of breakthrough topical ophthalmic investigational product BO-001 for the the treatment of glaucoma.

                            Brand Name : BO-001

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 03, 2024

                            Lead Product(s) : BO-001

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Recipient : Biophta

                            Deal Size : $6.9 million

                            Deal Type : Financing

                            HTL Biotechnology Biopolymer

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HTL Biotechnology

                            France
                            PCHi
                            Booth #5J24
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothHTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

                            Lead Product(s) : Regenerative Medicine,Hyaluronic Acid

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Recipient : GelMEDIX

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            HTL Announces Its Incubator's Equity Investment In GelMEDIX, An Early-Stage Biotech Aiming At Revolutionizing ...

                            Details : This investment supports development of the GelMEDIX platform, which enables the delivery of therapeutics from small molecules to cell and gene therapies. HTL will produce methacrylate hyaluronic acid, a key component for specific parameters across the G...

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 10, 2022

                            Lead Product(s) : Regenerative Medicine,Hyaluronic Acid

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Recipient : GelMEDIX

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            HTL Biotechnology Biopolymer

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            HTL Biotechnology

                            France
                            PCHi
                            Booth #5J24
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothHTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Eirion Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Eirion Therapeutics Announces Strategic Agreement for HTL Biotechnology to Become Eirion's Exclusive Botulinum...

                            Details : As part of the agreement, HTL will validate and operate botulinum manufacturing facility in US. Botulinum is the active ingredient in Eirion's lead product candidate ET-01, a topical neuromodulator being developed for Crow's Feet wrinkles and primary axi...

                            Brand Name : ET-01

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 08, 2021

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Eirion Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            HTL Biotechnology Biopolymer

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth